Biotechnology firm Oligomerix, Inc. announced that it has been awarded a US$0.5 million Phase I Fast-Track grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to advance its lead compound, OLX-07010. The company said the grant will fund non-clinical safety studies required to support future long-term dosing trials of OLX-07010 in Alzheimer’s disease (AD) patients.
According to Oligomerix, OLX-07010 is an orally administered small molecule designed to inhibit tau protein self-association and aggregation, a key pathological hallmark of Alzheimer’s and related neurodegenerative disorders. The company noted the urgency for effective Alzheimer’s therapies and positioned OLX-07010 as a cost-effective, pill-based alternative to current antibody-infusion approaches.
The awarded grant forms part of a broader drug development programme for OLX-07010: Oligomerix plans to use the data generated through these NIH-supported studies to underpin future Phase 1b and subsequently Phase 2 clinical trials in Alzheimer’s patients, with biomarker-based endpoints to assess disease modulation.
While the grant supports an important milestone, Oligomerix emphasised that the candidate remains in early development and that safety and efficacy in humans are yet to be demonstrated.
